The investigators want to understand the feasibility and acceptability of implementing COMPASS: Online Cognitive behavioural therapy (CBT) in routine NHS care for individuals with diabetes. People with type 1 or type 2 diabetes with co-morbid psychological distress will be invited to take part in a pre-post implementation study of COMPASS: Online CBT for managing depression and anxiety in context of Long-Term conditions (LTCs). Patients with diabetes who are also experiencing depression and/or anxiety and/or diabetes specific distress will be recruited from: Improving Access to Psychological therapies (IAPT) services or clinics within Guys and St Thomas National Health Service (NHS) trust (GSTT) in London, United Kingdom (UK).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Enrollment
12
COMPASS is an evidence based digital CBT intervention with guided therapist support, tailored to treat anxiety and/or depression in long term conditions (LTCs). The intervention consists of eleven modules/sessions in which CBT techniques are taught. Users of COMPASS receive guided therapist support from a trained therapist. The guided support aims to help patients identify and apply the CBT skills outlined in COMPASS to meet their individual needs and experiences of living with LTC(s). The support can occur through in-site messaging or via the telephone.
Guys Hospital
London, Other, United Kingdom
Emma Jenkinson
London, United Kingdom
King's College London
London, United Kingdom
South London and Maudsley
London, United Kingdom
To assess the socio-demographic and clinical reach of COMPASS.
Descriptive data, specifically frequencies documenting the number of individuals who are willing to use COMPASS, reasons documented for ineligibility/non-uptake and the sociodemographic and clinical profile of users vs non-users of COMPASS.
Time frame: To be collected throughout the study duration (the study will run for an average of 12 months).
To assess the socio-demographic and clinical reach of COMPASS.
Descriptive data on the types of treatment individuals with diabetes received throughout the study.
Time frame: To be collected throughout the study duration (the study will run for an average of 12 months).
To assess the socio-demographic and clinical reach of COMPASS.
Descriptive data documenting the number of individuals who consent to be contacted about research and subsequently give informed consent. The investigators will also report reasons for non-consent where this is disclosed.
Time frame: To be collected throughout the study duration (the study will run for an average of 12 months).
To explore the potential efficacy of COMPASS by examining pre-post change scores on self-reported mental health outcomes (listed below).
\- General psychological distress: Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS)
Time frame: To be collected at baseline, 12 weeks and 6 month follow up.
To explore the potential efficacy of COMPASS by examining pre-post change scores on self-reported mental health outcomes (listed below).
\- Depression: Patient health Questionnaire -9 (PHQ-9).
Time frame: To be collected at baseline, 12 weeks and 6 month follow up.
To explore the potential efficacy of COMPASS by examining pre-post change scores on self-reported mental health outcomes (listed below).
\- Anxiety: Generalised anxiety disorder assessment-7 (GAD-7)
Time frame: To be collected at baseline, 12 weeks and 6 month follow up.
To explore the potential efficacy of COMPASS by examining pre-post change scores on self-reported mental health outcomes (listed below).
\- Diabetes distress: Diabetes distress scale -17 (DDS-17)
Time frame: To be collected at baseline, 12 weeks and 6 month follow up.
To explore the potential efficacy of COMPASS by examining pre-post change scores on self-reported psychosocial outcomes (listed below).
\- Loneliness: The revised University of California Los Angeles Loneliness scale (UCLA-R)
Time frame: To be collected at baseline, 12 weeks and 6 month follow up.
To explore the potential efficacy of COMPASS by examining pre-post change scores on self-reported psychosocial outcomes (listed below).
\- Social Functioning: The Work and Social Adjustment Scale (WSAS)
Time frame: To be collected at baseline, 12 weeks and 6 month follow up.
To explore the potential efficacy of COMPASS by examining pre-post change scores on self-reported psychosocial outcomes (listed below).
\- Health Related Quality of Life: The European Quality of Life scale (EQ-5D-3L)
Time frame: To be collected at baseline, 12 weeks and 6 month follow up.
To explore the potential efficacy of COMPASS by examining pre-post change scores on self-reported physical health outcomes (listed below).
\- Glycaemic control: self-reported HbA1c levels.
Time frame: To be collected at baseline, 12 weeks and 6 month follow up.
To examine barriers and facilitators to the adoption of COMPASS from the perspective of both staff and patients.
Semi-structured interviews will be conducted to explore patient and health care professional (HCP) perceptions of the barriers and facilitators of using COMPASS in the context of diabetes.
Time frame: To be collected at 12 weeks.
To examine: i) number of patients who require digital support to use COMPASS ii) monthly referrals to COMPASS by staff.
The investigators will use descriptive statistics to quantify the number of patients who require digital support to use COMPASS and ii) monthly referrals to COMPASS by staff.
Time frame: To be collected at 12 weeks.
To assess the implementation of COMPASS in terms of patient adherence to COMPASS online sessions and number and duration of therapist support calls attended.
Descriptive data on number of online sessions completed and number and duration of therapist support calls attended will be extracted from the COMPASS program.
Time frame: To be collected throughout the study duration (the study will run for an average of 12 months).
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.